PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome

NCT02187250 on ClinicalTrials.gov · last registry update 2014-07-10

Finished June 2014, after enrolling 45 people. Primary outcome, as filed: The main outcome was change in body weight. liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University Medical Centre Ljubljana
Sponsor type: Other
Enrollment: 45
Started: 2014-03
Primary completion: 2014-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The main outcome was change in body weight.

Conditions studied

PCOS · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.